If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
105
results.
Updated on
16/02/2026 [07:00:00]
Absstract of: US20260041761A1
Provided are a pharmaceutical composition for resisting infection with SARS-COV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-COV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-COV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-COV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.
Absstract of: US20260041760A1
Prophylaxis, immune therapy and vaccine strategies for Covid-19 variants and comorbid conditions such as aging, diabetes, cancer, tuberculosis or HIV. In one mode of invention, the role of the C3 Amplification loop is defined and how it derails the SNS functions or immune function at fluid and tissue levels. The plasticity in subverting C3 amplification control mechanism contribute to survival strategies of SARS-CoV-2 that contributes to various variants that can be reactivated at any stage of life based on immune system of patient that may get compromised with comorbid diseases such as aging, diabetes, cancer and HIV. Therapeutic modulation takes into consideration plasticity of different patient needs and their comorbid conditions by developing varying formulation methods and its combination approaches.
Absstract of: US20260041762A1
The present invention relates to a production method of an inactivated SARS-CoV-2 vaccine, the method including: a step of bringing a SARS-CoV-2 containing solution or an inactivated SARS-CoV-2 containing solution into contact with a cellulose sulfate ester gel at a pH of 8 or more and 10 or less to adsorb the SARS-CoV-2 or the inactivated SARS-CoV-2 to the gel; then removing impurities; and then eluting and recovering the SARS-CoV-2 or the inactivated SARS-CoV-2.
Absstract of: WO2026031273A1
The present invention relates to the technical field of medicine and relates to a salt of a cyclic carbonate nucleoside compound and a crystal thereof, and a preparation method therefor and a use thereof. The salt of the cyclic carbonate nucleoside compound has a structure represented by formula I. When Y is hydrobromic acid and n=1, the salt of the nucleoside compound exists in crystal form A or crystal form B. Crystal form A has the advantages of good physical and chemical stability, good solid-state properties, good water solubility, low hygroscopicity, high oral bioavailability, etc., and can be used in the preparation of a drug for treating and/or alleviating related diseases caused by viruses (especially novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus, feline calicivirus, etc.).
Absstract of: US20260041751A1
The present invention provides a fusion protein which is useful as a vaccine antigen against infectious diseases. A fusion protein including (a) a combination of hemagglutinin and an N-terminal domain of SARS-COV-2, (b) a combination of PspA and a receptor binding domain of SARS-COV-2, (c) a combination of hemagglutinin and respiratory syncytial virus G protein, or (d) a combination of PspA and hemagglutinin, is useful as a vaccine antigen against infectious diseases.
Absstract of: US20260042743A1
The invention relates to benzimidazole compounds, pharmaceutically acceptable salts thereof and its pharmaceutical compositions for reducing/treating viral infections. The present invention also relates to synthesis of such benzimidazole compounds. The present invention further relates to compositions which comprise such benzimidazole compounds or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination. The compounds of the invention are useful in reducing/treating viral infections particularly coronavirus infections caused by SARS-CoV, MERS-CoV and SARS-CoV-2.
Absstract of: US20260041759A1
A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and/or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N/mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.
Absstract of: US20260041660A1
Methods and compositions containing a phorbol ester or derivative of a phorbol ester are provided for prevention and treatment of sudden acute respiratory syndrome (SARS) coronavirus infection, including SARS-COV-2 infection and related COVID-19 disease. Also provided are methods and compositions for preventing and treating acute inflammatory conditions and related pathogenic injuries, including Acute Respiratory Distress Syndrome (ARDS) and cytokine storm syndrome (CSS) seen in severe SARS-COV-2/COVID-19 cases.
Absstract of: EP4692109A1
It aims to provide a composition for inducing follicular helper T cell reactive to SARS-CoV-2. A partial peptide of the spike protein of SARS-CoV-2 is provided, which contains an amino acid sequence selected from the group consisting of the following (1) to (17) and has a full length of 15 or less amino acids:(1) FKIYSKHTPIN (SEQ ID NO: 1),(2) FQFCNDPFLGVYYHK (SEQ ID NO: 2),(3) KRFDNPVLPFN (SEQ ID NO: 3),(4) LLQYGSFCTQL (SEQ ID NO: 4),(5) PPAYTNSFTRGVYYP (SEQ ID NO: 5),(6) CSNLLLQYGSFCTQL (SEQ ID NO: 6),(7) SKRSFIEDLLFNKVT (SEQ ID NO: 7),(8) TGVLTESNKKFLPFQ (SEQ ID NO: 8),(9) TNGTKRFDNPVLPFN (SEQ ID NO: 9),(10) NQFNSAIGKIQ (SEQ ID NO: 10),(11) NFTISVTTEIL (SEQ ID NO: 11),(12) STEIYQAGSTPCNGV (SEQ ID NO: 12),(13) KVFRSSVLHST (SEQ ID NO: 13),(14) EIRASANLAAT (SEQ ID NO: 14),(15) NFTISVTTEILPVSM (SEQ ID NO: 15),(16) FIKQYGDCLGDIAAR (SEQ ID NO: 16), and(17) FIEDLLFNKVTLADA (SEQ ID NO: 17).
Absstract of: AU2024308310A1
The present disclosure relates to SARS-CoV-2 RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of a SARS-CoV-2 infection or COVID-19.
Absstract of: US20260034208A1
The present disclosure relates to the discovery of compositions and methods for therapeutic immunization for SARS-CoV-2 infections and/or disease(s) associated with expression of Glypican-3 (GPC3), including but not limited to cancers such as hepatocellular carcinoma (HCC). Methods of the disclosure include a method of generating virus like vesicles (VLVs), VLVs comprising SARS-CoV-2 antigens from a high titer VLV producing vector, VLVs comprising GPC3 antigens from a high titer VLV producing vector, methods of treating, ameliorating, and/or preventing SARS-COV-2 infection, methods of inducing a memory T and B cell immune response against SARS-CoV-2 infection in a, methods of treating, ameliorating, and/or preventing GPC3 associated disease, and methods of inducing a memory T and B cell immune response against GPC3 in a subject. Furthermore, the disclosure encompasses a pharmaceutical composition for vaccinating a subject to protect the subject against infection with
Absstract of: US20260035439A1
Provided herein are monoclonal antibodies that specifically bind to an anti-SARS-CoV-2 spike(S) protein, and methods of using said antibodies.
Absstract of: US20260034209A1
An SARS-COV-2 recombinant Spike protein is provided. The research process of the protein is as follows: the dominant strain in circulation was identified by screening clinical samples of SARS-COV-2 patients and its mutations in Turkey were evaluated by sequencing the Spike gene. Sequencing data and in silico methods were used to design the Spike antigen and then the novel Spike antigen was docked with the human ACE2 (Angiotensin Converting Enzyme-2) receptor to determine the binding energy. After DNA vaccine construction, HEK293T cells were transfected and analyzed for protein expression capacity by IFA, Western blot and RT-qPCR, then BALB/c mice and K18-hACE2 transgenic mice were immunized with DNA vaccine administered intramuscularly (IM) and intradermally (ID) using an electroporator device three times on days 0, 14 and 56. Humoral and cellular immune responses were then analyzed using recombinant ELISA, Western blot, surrogate virus neutralization assay, microneutralization assay, Cytokine ELISA and flow cytometry.
Absstract of: WO2026030604A1
The present invention includes a monoclonal antibody or antigen-binding fragment thereof, methods of using, detection, recombinant vectors, host cells, kits, variants, and pharmaceutical compositions that include the antibody or antigen-binding fragment thereof that binds to the SARS-CoV-2 Spike protein.
Absstract of: US20260035438A1
The invention provides novel broadly neutralizing antibodies and related antibody compositions against betacoronaviruses, e.g., SARS-CoV-2. Also provided in the invention are polynucleotides and vectors encoding such antibodies, as well as pharmaceutical compositions containing the antibodies or polynucleotides. Therapeutic uses of the antibodies or pharmaceutical compositions in preventing or treating betacoronaviral infections (e.g., SARS-CoV-2 infection) are also encompassed by the invention.
Absstract of: US20260034097A1
Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).
Absstract of: WO2026030724A1
Provided herein are recombinant SARS-CoV-2 Spike proteins and fragments thereof comprising the receptor binding domain (RBD), which have utility, for example, for elicitation of an immune response to SARS-CoV-2 in a subject. Also provided are nucleic acid molecules and vectors encoding these proteins, as well as methods of their use and production. In several implementations, the disclosed recombinant SARS-CoV-2 Spike proteins and fragments thereof comprising the RBD, can be used to generate an immune response to SARS-CoV-2 in a subject, for example to treat or prevent or reduce the severity of SARS-CoV-2 infection.
Absstract of: WO2026029035A1
The purpose of the present invention is to provide an antibody against a coronavirus (SARS-CoV-2) mutant strain, in particular, an omicron substrain. Moreover, another purpose of the present invention is to provide a pharmaceutical composition against coronavirus infections, the pharmaceutical composition using said antibody. The present invention provides: an antibody that binds to a spike protein of coronavirus and has the ability to neutralize coronavirus including an omicron substrain, or an antigen-binding fragment thereof; and a pharmaceutical composition for preventing or treating coronavirus infections, the pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.
Absstract of: EP4686470A1
The present invention refers to macrocyclic peptides as covalent reversible inhibitors of SARS-CoV-2 M<sup>pro</sup> with a potential broad-spectrum activity against CoV proteases. The compounds are therefore indicated for treating M<sup>pro</sup> associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
Absstract of: MX2025014589A
The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).
Absstract of: MX2024009232A
The present application is in the field of genetic engineering, biotechnological and in particular in the design and production of synthetic genes in different strains of Escherichia coli resulting in soluble molecules with antigenic capacity against the SARS-CoV2 virus. This method is summarized in three phases which are: The application of molecular engineering for obtaining the DNA sequence that allows E coli to produce SARS-CoV2 viral antigens, followed by integration of the designed vector into E coli cells to obtain recombinant strains and finally the production and purification of recombinant viral antigens of SARS-CoV2 in E coli.
Absstract of: MX2025011740A
An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 µg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-CoV-2, a heterogeneous SARS-CoV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.
Absstract of: RS20240787A1
Method and device for applying an electrical stimulus to an acupuncture point using an electrode connected to ground on a patient exposed to the emitted electromagnetic field of a Tesla transformer. The intention of the invention is increasing the effectiveness of acupuncture treatment, while making its use painless for the general population, and especially suitable for the pediatric population. The device can be used to relieve symptoms and pain caused by trauma, post-Covid 19 syndrome, for prevention of worsening of such symptoms, for the prevention and treatment of symptoms associated with depression and other psychiatric, neurological and developmental disorders, including major depressive disorder, Alzheimer's disease and autism. The device consists of a Tesla transformer (1) and an electrode or set of electrodes (6) connected to an electrical ground (4). The Tesla transformer (1) consists of a primary coil (1.a), a secondary coil (1.b), a feedback coil (1.c) and a control circuit (2). The system also includes a variable resistor (7), which regulates the radiation intensity of the Tesla transformer (1).
Absstract of: NZ791834A
Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject.
Nº publicación: AU2024335376A1 29/01/2026
Applicant:
PT JAWAHAR LAL NEHRU MEMORIAL MEDICAL COLLEGE
PAL JAGANNATH
INDIAN COUNCIL OF MEDICAL RES
PT. JAWAHAR LAL NEHRU MEMORIAL MEDICAL COLLEGE,
PAL, Jagannath,
INDIAN COUNCIL OF MEDICAL RESEARCH
Absstract of: AU2024335376A1
The present disclosure relates to in vitro identification of neutralizing antibody against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Specifically, the present disclosure relates a kit and an in vitro assay for analyzing the presence of neutralizing antibody/inhibitors which could block or inactivate receptor binding domain of the spike protein of SARS-CoV-2.
BOPI
Electronic site
